Phase 3 KEYNOTE-042 Study: Pembrolizumab vs Platinum-Based Chemotherapy as 1l Therapy for Advanced NSCLC with a PD-L1 TPS >= 1%

G Lopes; Y Wu; I Kudaba; D Kowalski; B Cho; H Turna; G De Castro; V Srimuninnimit; K Laktionov; I Bondarenko; K Kubota; G Lubiniecki; J Zhang; D Kush; T Mok

doi:10.1016/j.jtho.2018.07.020

Phase 3 KEYNOTE-042 Study: Pembrolizumab vs Platinum-Based Chemotherapy as 1l Therapy for Advanced NSCLC with a PD-L1 TPS >= 1%

G Lopes, Y Wu, I Kudaba, D Kowalski, B Cho, H Turna, G De Castro, V Srimuninnimit, K Laktionov, I Bondarenko, K Kubota, G Lubiniecki, J Zhang, D Kush, T Mok

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	S152
Number of pages	1
Journal	Journal of Thoracic Oncology
Volume	13
Issue number	9, Suppl.
DOIs	https://doi.org/10.1016/j.jtho.2018.07.020
Publication status	Published - Sept 2018
Externally published	Yes
Event	IASLC Latin American Conference on Lung Cancer - Cordoba, Argentina Duration: 15 Aug 2018 → 18 Aug 2018 https://www.emedevents.com/c/medical-conferences-2018/latin-american-lung-cancer-conference-lalca-2018-1 https://www.sciencedirect.com/journal/journal-of-thoracic-oncology/vol/13/issue/9/suppl/S

Keywords*

KEYNOTE-042
Chemotherapy
Pembrolizumab
Programmed death ligand 1 (PD-L1)

Field of Science*

3.2 Clinical medicine

Publication Type*

3.3. Publications in conference proceedings indexed in Web of Science and/or Scopus database

Access to Document

10.1016/j.jtho.2018.07.020

Cite this

Lopes, G., Wu, Y., Kudaba, I., Kowalski, D., Cho, B., Turna, H., De Castro, G., Srimuninnimit, V., Laktionov, K., Bondarenko, I., Kubota, K., Lubiniecki, G., Zhang, J., Kush, D., & Mok, T. (2018). Phase 3 KEYNOTE-042 Study: Pembrolizumab vs Platinum-Based Chemotherapy as 1l Therapy for Advanced NSCLC with a PD-L1 TPS >= 1%. Journal of Thoracic Oncology, 13(9, Suppl.), S152. https://doi.org/10.1016/j.jtho.2018.07.020

@article{028bf922eb4f44779e38161c03d8fa5d,

title = "Phase 3 KEYNOTE-042 Study: Pembrolizumab vs Platinum-Based Chemotherapy as 1l Therapy for Advanced NSCLC with a PD-L1 TPS >= 1%",

keywords = "KEYNOTE-042, Chemotherapy, Pembrolizumab, Programmed death ligand 1 (PD-L1)",

author = "G Lopes and Y Wu and I Kudaba and D Kowalski and B Cho and H Turna and {De Castro}, G and V Srimuninnimit and K Laktionov and I Bondarenko and K Kubota and G Lubiniecki and J Zhang and D Kush and T Mok",

year = "2018",

month = sep,

doi = "10.1016/j.jtho.2018.07.020",

language = "English",

volume = "13",

pages = "S152",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",

publisher = "Elsevier Inc.",

number = "9, Suppl.",

note = "IASLC Latin American Conference on Lung Cancer ; Conference date: 15-08-2018 Through 18-08-2018",

url = "https://www.emedevents.com/c/medical-conferences-2018/latin-american-lung-cancer-conference-lalca-2018-1, https://www.sciencedirect.com/journal/journal-of-thoracic-oncology/vol/13/issue/9/suppl/S",

}

Lopes, G, Wu, Y, Kudaba, I, Kowalski, D, Cho, B, Turna, H, De Castro, G, Srimuninnimit, V, Laktionov, K, Bondarenko, I, Kubota, K, Lubiniecki, G, Zhang, J, Kush, D & Mok, T 2018, 'Phase 3 KEYNOTE-042 Study: Pembrolizumab vs Platinum-Based Chemotherapy as 1l Therapy for Advanced NSCLC with a PD-L1 TPS >= 1%', Journal of Thoracic Oncology, vol. 13, no. 9, Suppl., pp. S152. https://doi.org/10.1016/j.jtho.2018.07.020

TY - JOUR

T1 - Phase 3 KEYNOTE-042 Study

T2 - IASLC Latin American Conference on Lung Cancer

AU - Lopes, G

AU - Wu, Y

AU - Kudaba, I

AU - Kowalski, D

AU - Cho, B

AU - Turna, H

AU - De Castro, G

AU - Srimuninnimit, V

AU - Laktionov, K

AU - Bondarenko, I

AU - Kubota, K

AU - Lubiniecki, G

AU - Zhang, J

AU - Kush, D

AU - Mok, T

PY - 2018/9

Y1 - 2018/9

KW - KEYNOTE-042

KW - Chemotherapy

KW - Pembrolizumab

KW - Programmed death ligand 1 (PD-L1)

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=rsu_pure_&SrcAuth=WosAPI&KeyUT=WOS:000444519200002&DestLinkType=FullRecord&DestApp=WOS

UR - https://www-webofscience-com.db.rsu.lv/wos/alldb/full-record/WOS:000444519200002

U2 - 10.1016/j.jtho.2018.07.020

DO - 10.1016/j.jtho.2018.07.020

M3 - Meeting Abstract

SN - 1556-0864

VL - 13

SP - S152

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

IS - 9, Suppl.

Y2 - 15 August 2018 through 18 August 2018

ER -

Phase 3 KEYNOTE-042 Study: Pembrolizumab vs Platinum-Based Chemotherapy as 1l Therapy for Advanced NSCLC with a PD-L1 TPS >= 1%

Keywords*

Field of Science*

Publication Type*

Access to Document

Other files and links

Cite this